Tina H. Tran

Tina H. Tran

Auto-generated profile, based on publicly available information

Tina H. Tran

Division of Pediatric Surgery, Oregon Health & Science University School of Medicine, Portland, OR, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2020 in Analytical Chemistry
Verified
Journal Article
Closed access
LSLaith Z. Samarah
Laith Z. Samarah
RKRikkita Khattar
Rikkita Khattar
TTTina H. Tran
Tina H. Tran
SSSylwia A. Stopka
Sylwia A. Stopka
CBChristine Brantner
Christine Brantner
Akos VertesAkos Vertes
Akos Vertes

28 April 2020 in Analytical Chemistry
Verified
Journal Article
Closed access
LSLaith Z. Samarah
Laith Z. Samarah
TTTina H. Tran
Tina H. Tran
GSGary Stacey
Gary Stacey
Akos VertesAkos Vertes
Akos Vertes

16 September 2022 in Journal of Surgical Oncology
Verified
Journal Article
Open access
KTKara S. Tanaka
Kara S. Tanaka
VAVeronica R. Andaya
Veronica R. Andaya
STSteven W. Thorpe
Steven W. Thorpe
KGKenneth R. Gundle
Kenneth R. Gundle
JHJames B. Hayden
James B. Hayden
OFother members of Study Group FORCE
other members of Study Group FORCE
Background: Expandable endoprostheses can be used to equalize limb length for pediatric patients requiring reconstruction following large bony oncologic resections. Outcomes of the Compress® Compliant Pre‐Stress (CPS) spindle paired with an Orthopedic Salvage System expandable distal femur endoprosthesis have not been reported.Methods: We conducted a multi‐institutional retrospective study of pediatric patients with distal femoral bone sarcomas reconstructed with the above endoprostheses. Statistical analysis utilized Kaplan–Meier survival technique and competing risk analysis.Results: Thirty‐six patients were included from five institutions. Spindle survivorship was 86.3% (95% confidence interval [CI], 67.7–93.5) at 10 years. Two patients had a failure of osseointegration (5.7%), both within 12 months. Twenty‐two (59%) patients had 70 lengthening procedures, with mean expansions of 3.2 cm (range: 1–9) over 3.4 surgeries. The expandable mechanism failed in eight patients with a cumulative incidence of 16.1% (95% CI, 5.6–31.5) at 5 years. Twenty‐nine patients sustained International Society of Limb Salvage failures requiring 63 unplanned surgeries. Periprosthetic joint infection occurred in six patients (16.7%). Limb preservation rate was 91% at 10 years.Conclusions: There is a high rate of osseointegration of the Compress® spindle among pediatric patients when coupled with an expandable implant. However, there is a high rate of expansion mechanism failure and prosthetic joint infections requiring revision surgery.Level of evidence: Level IV, therapeutic study.

19 August 2025 in Journal of Pediatric Surgery
Verified
Journal Article
Open access
UPUtsav M. Patwardhan
Utsav M. Patwardhan
GSGretchen Floan Sachs
Gretchen Floan Sachs
RIRomeo L. Ignacio
Romeo L. Ignacio
BPBenjamin Padilla
Benjamin Padilla
JLJustin Lee
Justin Lee
RIRomeo C. Ignacio
Romeo C. Ignacio
Guidelines for adult gallstone pancreatitis (GP) in adults recommend endoscopic retrograde cholangiopancreatography (ERCP) for ongoing biliary obstruction. Studies in children are limited by small sample sizes. We sought to explore whether factors predictive of choledocholithiasis (CDL) are correlated with ERCP findings of stones in pediatric GP. We analyzed a subgroup of GP patients from a retrospective pediatric cohort undergoing cholecystectomy across ten hospitals from 2016 to 2019. Those with incomplete records and cholangitis were excluded. The absence of CDL was defined as ERCP that was either negative or not performed because of the resolution of obstruction. Comparative analyses were made between ERCP and non-ERCP patients. Among 1601 children undergoing cholecystectomy, 125 with GP were identified of which 30 (24 %) underwent preoperative ERCP. ERCP patients had a greater mean bilirubin (4.1 vs. 2.4, p = 0.02), median CBD diameter (9 vs. 5 mm, p <0 .001), and visualized stone on MRCP (36.7 vs. 4.2 %, p < 0.001). However, among patients with hyperbilirubinemia (≥1.8 mg/dL) or a dilated CBD (≥6 mm), 71 % of patients did not have CDL. In contrast, only 40 % of patients with a visualized stone on MRCP had a negative ERCP. ERCP was not associated with prolonged length of stay (LOS) or readmissions. In children with GP, hyperbilirubinemia and CBD dilation were not reliable predictors of a positive ERCP, potentially leading to unnecessary radiation and/or anesthesia. MRCP with visualized stone was the best predictor of CDL. Although ERCP did not result in greater LOS or readmissions, the use of MRCP prior to ERCP may reduce unnecessary procedures for children with gallstone pancreatitis.

17 June 2025 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
YDYesenia Day
Yesenia Day
ATAustin R. Thompson
Austin R. Thompson
VAVeronica R. Andaya
Veronica R. Andaya
KSKaitlyn Smith
Kaitlyn Smith
YDYee‐Cheen Doung
Yee‐Cheen Doung
RWRosanna L. Wustrack
Rosanna L. Wustrack

12 October 2026 in JPGN Reports
Verified
Journal Article
Open access
PDF file
TTTina H. Tran
Tina H. Tran
DPDaniel Park
Daniel Park
RARegina‐Celeste Ahmad
Regina‐Celeste Ahmad
MGMalika Goel
Malika Goel
SVSofia Verstraete
Sofia Verstraete
SASabina Ali
Sabina Ali
Janus kinase inhibitors (JAKi) are increasingly used for refractory inflammatory bowel disease (IBD) in pediatric patients but are associated with significant dermatologic adverse effects. Acneiform eruptions have been reported in up to 30% of adults, with a greater incidence suspected in adolescents. We performed a retrospective review of 66 pediatric IBD patients treated with JAKi at UCSF Benioff Children's Hospitals (2022–2025), including 41 on upadacitinib and 25 on tofacitinib. Eight patients (12.1%) developed new‐onset or worsening moderate to severe acne requiring dermatology referral for management; rates were higher with upadacitinib (6/41, 14.6%) than tofacitinib (2/25, 8.0%). Acne onset was early (median 3.5 weeks) and predominantly inflammatory. Four patients required JAKi discontinuation, and two developed acne fulminans requiring hospitalization. Management often required systemic therapy and multidisciplinary care. These findings highlight the need for anticipatory counseling, early recognition, and prompt dermatologic involvement to reduce morbidity and support continuation of effective IBD therapy.